DYRK1A and gastric cancer: Given the intricate pathogenesis of gastric cancer and the limited efficacy of current metastasis‐targeted interventions, innovative therapeutic strategies—such as circRNA‐based modulation, OGT inhibitors, and DYRK1A kinase‐targeted therapy—are urgently needed.